Univercells Technologies provides innovative biomanufacturing technologies to help customers achieve cost-effective advanced therapies and vaccines production from R&D to commercial scales. The company delivers a range of technologies leveraging the strengths of process intensification and chaining: the scale-X™ high cell density fixed-bed bioreactor for both adherent and suspension intensified processing, as well as the integrated, low-footprint NevoLine™ Upstream manufacturing platform for cost-effective commercial manufacturing. Incorporated in Belgium in 2020 and now a Donaldson company, Univercells Technologies’ biomanufacturing technologies are globally installed and used in GMP clinical stages, and for a variety of cell lines and products such as VERO, AAV, Exosomes, VSV, Adenovirus, etc.